ABOUT TMUNITY THERAPEUTICS

Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to more patients with devastating diseases.

 

Integrating broad collaborations with the University of Pennsylvania (UPenn) and the University of Minnesota with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders, Tmunity is developing personalized immunotherapies for cancer, infectious disease and autoimmune disease that are advancing rapidly toward the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at UPenn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of T cell therapies.

LATEST NEWS

November 06, 2019

Early Results from First-In-U.S. Trial of CRISPR-Edited Immune Cells for Cancer Patients Suggest Safety of Approach

November 04, 2019

Tmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients

Please reload

Tmunity is the new center of gravity in translational T cell medicine, inventing the future of cell-based immunotherapy today.

Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body.

“Extraordinary advances have already been made with the development of the first generation of cell-based immunotherapies for cancer. We formed Tmunity, bringing together all the essential expertise, technology and scientific insight, to make the next great leap, to deliver the full promise of T cell medicine to patients.”

Carl H. June, MD

Legal  |  Privacy  |  Cookies

Tmunity Therapeutics Inc.
3020 Market Street, Suite 535
Philadelphia, PA 19104

+1 215 966 1600

© 2018 Tmunity Therapeutics. All rights reserved.